An interventional study of Immediately placed implant in maxillary premolars with local melatonin application and Immediately placed implant in maxillary premolars without local melatonin application in Dental Implants, Osteoprotegerin and Melatonin, sponsored by Hams Hamed Abdelrahman. Completed at 1 site in Egypt. Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Hams Hamed Abdelrahman · Not applicable, Interventional, and Treatment
Background: Immediate implants provide ideal three-dimensional positioning compared to conventional implants. There may be a gap between the surface of the implant and the bone walls of the socket when it is inserted into a recently extracted alveolus. To compensate for this, various grafting materials are used. Recently, melatonin has gained significant attention because of its inhibitory action on bone resorption through upregulating the expression of osteoprotegerin, which acts as a decoy receptor for RANKL and inhibits its binding to osteoclast precursors thereby inhibiting osteoclast formation and activity. So, we will conduct this study to evaluate the effects of local melatonin application around immediately placed implants.
Aim of the study: To evaluate the effectiveness of adding local melatonin around immediately placed implants in maxillary premolars.
Hams Hamed Abdelrahman is the lead sponsor of 107 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Immediately placed implant in maxillary premolars with local melatonin application
Other: Immediately placed implant in maxillary premolars without local melatonin application
Patients will receive immediately placed implants with local melatonin powder (3mg) application.
Patients will receive immediately placed implants without local melatonin application.
Change in Osteoprotegerin
OPG (Ng/ml) level will be measured preoperatively, 1 and 3 months post operatively, to evaluate the bone healing activity. The level will be evaluated by collecting 5 ml of peripheral blood in blank tubes and will be allowed for complete clotting and will be centrifuged at 1000 g for 15 min. The separated serum will be then stored at -20 0C.
Time frame: Baseline, 1 month, and 3 months
Change in bone volume
CBCT scans will be obtained to measure change in bone volume
Time frame: Baseline and 6 months
Change in bone level
CBCT scans will be obtained to measure change in bone level
Time frame: Baseline and 6 months
Change in bone density
CBCT scans will be obtained to measure change in bone density
Time frame: Baseline and 6 months
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hams Hamed Abdelrahman